Piper Jaffray set a $145.00 price objective on Inogen (NASDAQ:INGN) in a research note issued to investors on Saturday morning. The brokerage currently has a buy rating on the medical technology company’s stock.
INGN has been the topic of a number of other reports. Zacks Investment Research lowered Inogen from a buy rating to a hold rating in a research report on Wednesday, January 10th. BidaskClub upgraded Inogen from a sell rating to a hold rating in a research note on Wednesday, January 24th. ValuEngine upgraded Inogen from a hold rating to a buy rating in a research note on Friday, April 6th. Finally, Needham & Company LLC lifted their price target on Inogen from $125.00 to $150.00 and gave the stock a strong-buy rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $115.14.
Shares of NASDAQ INGN opened at $139.43 on Friday. Inogen has a 1 year low of $74.90 and a 1 year high of $143.00. The stock has a market cap of $2,947.02, a PE ratio of 106.44, a price-to-earnings-growth ratio of 3.86 and a beta of 1.03.
Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.10. Inogen had a return on equity of 13.47% and a net margin of 8.42%. The business had revenue of $63.79 million for the quarter, compared to analyst estimates of $62.01 million. research analysts predict that Inogen will post 1.6 EPS for the current year.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $127.95, for a total value of $319,875.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Heather D. Rider sold 5,222 shares of Inogen stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $131.13, for a total value of $684,760.86. Following the completion of the transaction, the director now owns 3,222 shares of the company’s stock, valued at $422,500.86. The disclosure for this sale can be found here. Insiders sold 112,218 shares of company stock valued at $13,570,316 over the last quarter. Insiders own 5.29% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Lenox Wealth Advisors Inc. acquired a new position in Inogen in the fourth quarter valued at approximately $100,000. Steward Partners Investment Advisory LLC boosted its stake in Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock valued at $130,000 after acquiring an additional 1,000 shares during the period. Simplex Trading LLC acquired a new position in Inogen in the fourth quarter valued at approximately $153,000. LS Investment Advisors LLC boosted its stake in Inogen by 138.6% in the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock valued at $180,000 after acquiring an additional 880 shares during the period. Finally, Everence Capital Management Inc. acquired a new position in Inogen in the fourth quarter valued at approximately $208,000. Institutional investors own 98.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Piper Jaffray Reiterates “$145.00” Price Target for Inogen (INGN)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/17/piper-jaffray-reiterates-145-00-price-target-for-inogen-ingn.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.